13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2
- CAS No.
- 363-23-5
- Chemical Name:
- 13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2
- Synonyms
- PGEM;13,14-Dihydro-15-keto-PGE2;CUJMXIQZWPZMNQ-XYYGWQPLSA-N;15-keto-13,14-dihydroprostaglandine2;13,14-dihydro-15-oxo-prostaglandin E2;13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2;13,14-Dihydro-15-ketoprostaglandinE2 solution;9,15-DIOXO-11ALPHA-HYDROXY-PROST-5Z-EN-1-OIC ACID;(5Z)-11α-Hydroxy-9,15-dioxoprosta-5-ene-1-oic acid;(5Z,11α)-11-Hydroxy-9,15-dioxoprost-5-en-1-oic acid
- CBNumber:
- CB8349316
- Molecular Formula:
- C20H32O5
- Molecular Weight:
- 352.47
- MOL File:
- 363-23-5.mol
- Modify Date:
- 2023/6/8 9:01:56
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS07,GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H312-H315-H319-H332-H335-H351 | |||||||||
| Precautionary statements | P261-P280-P305+P351+P338 | |||||||||
| Hazard Codes | F,Xn,Xi | |||||||||
| Risk Statements | 11-20/21/22-36/37/38-67-66-36 | |||||||||
| Safety Statements | 16-26-36 | |||||||||
| RIDADR | UN 1231 3/PG 2 | |||||||||
| WGK Germany | 3 | |||||||||
| NFPA 704 |
|
13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2 Chemical Properties,Uses,Production
Description
13,14-dihydro-15-keto Prostaglandin E2 (13,14-dihydro-15-keto PGE2) is a metabolite of PGE2 and the primary PGE2 metabolite in plasma. It is formed from PGE2 via a 15-keto PGE2 intermediate by 15-oxo-PG Δ13 reductase. Unlike PGE2, 13,14-dihydro-15-keto PGE2 does not bind effectively to the PGE2 receptors EP2 and EP4 expressed in CHO cells (Kis = 12 and 57 μM, respectively) or induce adenylate cyclase activity in the same cells (EC50s = >18 and >38 μM, respectively). Levels of 13,14-dihydro-15-keto PGE2 are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery. Levels of 13,14-dihydro-15-keto PGE2 levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC).
Uses
13,14-Dihydro-15-ketoPGE2 is a primary metabolite of PGE2 in plasma.
Definition
ChEBI: The 13,14-dihydro derivative of 15-oxo-prostaglandin E2.
13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2 Preparation Products And Raw materials
Raw materials
Preparation Products
13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 | China | 8474 | 58 | Inquiry |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | China | 9708 | 58 | Inquiry |
| Shanghai Aladdin Biochemical Technology Co.,Ltd. | +86-18521732826 | China | 48467 | 58 | Inquiry |
| ChemeGen(Shanghai) Biotechnology Co.,Ltd. | 18818260767 | China | 11289 | 58 | Inquiry |
| amyjetsci | 027-59626688 18771149750 | China | 3004 | 58 | Inquiry |
| Hubei Kele Fine Chemical Co., Ltd | 027-59101668 19945030958 | China | 7972 | 58 | Inquiry |
| Biomol Feinchemikalien GmbH | 49-40-8532600 | Germany | 479 | 74 | Inquiry |
| Spectrum Info. Ltd. | 380 44 573 23 97 | Ukraine | 2742 | 53 | Inquiry |
| Interchim S.A. | (33) 4 70 03 88 55 | France | 6307 | 76 | Inquiry |
| SIGMA-RBI | 800 736 3690 (Orders) | Switzerland | 6913 | 91 | Inquiry |
363-23-5(13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2)Related Search:
1of4
chevron_right